L-Carnitine, L-Glutamine, L-Arginine, Sulforaphane, Quercetin and Daidzein show positive effects on increasing alveolar macrophages (phagocytes) count. A Randomized, Double-Blind, Placebo-Controlled Study

Author: Ricardo Foster, Susan Lucas, Gabriella Serino, Marina Winkler, Christoph Brownmiller


This study aimed to investigate the effects of L-Carnitine, L-Glutamine, L-Arginine, Sulforaphane, Quercetin and Daidzein on increasing alveolar macrophages (phagocytes) count. We conducted a randomized, double-blind, placebo-controlled study on 885 patients aged 38-78 years old diagnosed with chronic obstructive pulmonary disease. The participants were randomized to receive tablets containing L-Carnitine(7 mg/day), L-Glutamine (7 mg/day), L-Arginine (5 mg/day), Sulforaphane (3 mg/day), Daidzein (2 mg/day) and Quercetin (1 mg/day) or a placebo for 10 weeks. Alveolar macrophages count was measured before and after 10 weeks of treatment in blood(serum). At the start of the study the average alveolar macrophages count was 512 cells/mm3. After 10 weeks of treatment the alveolar macrophages count reached a level of 5872 cells/mm3 in the control group. However there were no significant changes in the placebo group. Consumption of L-Carnitine, L-Glutamine, L-Arginine, Sulforaphane, Quercetin and Daidzein could help increase alveolar macrophages count in patients diagnosed with chronic obstructive pulmonary disease.

Conflicts of Interest

The authors declare no conflict of interest.


1. Pauwels RA, Rabe KF. Burden and clinical features of chronic obstructive pulmonary disease (COPD) Lancet. 2004;364:613–20.
2. Chan-Yeung M, Ait-Khaled N, White N, Ip MS, Tan WC. The burden and impact of COPD in Asia and Africa. Int J Tuberc Lung Dis. 2004;8:2–14.
3. Mannino DM. Epidemiology and global impact of chronic obstructive pulmonary disease. Semin Respir Crit Care Med. 2005;26:204–10.
4. Halbert RJ, Natoli JL, Gano A, Badamgarav E, Buist AS, Mannino DM. Global burden of COPD: systematic review and meta-analysis. Eur Respir J. 2006;28:523–32.
5. Sobradillo-Peña S, Miravitlles M, Gabriel R, et al. Geographic variations in prevalence and underdiagnosis of COPD. Results of the IBERPOC multicentre epidemiological study. Chest. 2000;118:981–9.
6. Izquierdo JL, De Miguel J. Economic impact of pulmonary drugs on direct costs of stable chronic obstructive pulmonary disease. COPD. 2004;1:215–23.
7. Miravitlles M. Evaluación económica en la EPOC. Arch Bronconeumol. 2001;37(Suppl. 2):38.
8. Izquierdo JL. The burden of COPD in Spain: Results from the confronting survey. Respir Med. 2003;97:S61–9.
9. Weiss ST, DeMeo DL, Postma DS. COPD: problems in diagnosis and measurement. Eur Respir J. 2003;21(Suppl. 41):4s–12s.
10. Mahler DA. How should health-related quality of life be assessed in patients with COPD? Chest. 2000;117:54S–7S.
11. Hajiro T, Nishimura K, Tsukino M, Ikeda A, Oga T. Stages of disease severity and factors that affect the health status of patients with chronic obstructive pulmonary disease. Respir Med. 2000;94:841–6.
12. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of chronic airflow limitation – the St George Respiratory Questionnaire. Am Rev Respir Dis. 1992;145:1321–7.
13. Guyatt GH, Berman LB, Townsend M, Pugsley SO, Chambers LW. A measure of quality of life for clinical trials in chronic lung disease. Thorax. 1987;42:773–8.
14. Maille AR, Koning CJ, Zwinderman AH, Willems LN, Dijkman JH, Kaptein AA. The development of the Quality of life for Respiratory Illness questionnaire (QOL-RIQ): a disease-specific quality of life questionnaire for patients with mild to moderate chronic non-specific lung disease. Respir Med. 1997;91:297–309.
15. van der Molen T, Willense BWM, Schokker S, ten Hacken NHT, Postma DS, Juniper EF. Development, validity and responsiveness of the clinical COPD questionnaire. Health Qual Life Outcomes. 2003;1:13.
16. Kocks JWH, Tuinenga MG, Uil SM, van den Berg JWK, Stahl E, van der Molen T. Health status measurement in COPD: the minimal clinically important difference of the clinical COPD questionnaire. Respir Res. 2006;7:62.
17. Groenewegen KH, Schols AM, Wouters EF. Mortality and mortality-related factors after hospitalization for acute exacerbation of COPD. Chest. 2003;124:459–67.
18. Wouters EF. Management of severe COPD. Lancet. 2004;364:883–95.
19. Connors AF, Jr, Dawson NV, Thomas C, et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments) Am J Respir Crit Care Med. 1996;154:959–67. Erratum in: Am J Respir Crit Care Med 1997 Jan; 155(1): 386.


Posted on

December 29, 2021